







Table 1: Plaque diameters of HSV-1 and HSV-2 isolates and strains treated with AS and 838

HSV Strains	VND	AS-10 μ M	AS-50 μ M	838-1 μ M	838-10 μ M
HSV-1-clinical	0.50 \pm 0.07	0.52 \pm 0.07	0.30 \pm 0.05	0.47 \pm 0.08	0.30 \pm 0.09
HSV-1-luciferase	0.45 \pm 0.05	0.40 \pm 0.05	0.35 \pm 0.03	0.40 \pm 0.04	0.36 \pm 0.04
HSV2-clinical (2)	0.67 \pm 0.05	0.61 \pm 0.03	0.62 \pm 0.10	0.44 \pm 0.03	0.39 \pm 0.11
HSV2-clinical (4)	0.54 \pm 0.04	0.56 \pm 0.07	0.54 \pm 0.08	0.45 \pm 0.07	0.35 \pm 0.07

Plaque diameters are shown in millimeter (mm). Mean values (\pm SD) of six determinations from two independent experiments are shown. VND- virus no drug



Supporting Information

Figure S1: Effects of add-on and removal of compounds on CMV DNA replication and virus yield. Inhibition of virus yield by AS, 838 and GCV was measured by US 17 real-time PCR in supernatants collected at 96 hpi (A and B). Inhibition of viral DNA replication was measured by real-time PCR from purified cell and virus DNA collected at 48 hpi (C and D) and at 72 hpi (E and F), respectively. Compounds were added (A, C and E) or removed (B, D and F) at the indicated time points. Data represent mean values (\pm SD) of triplicate determinations from two independent experiments.